Drug intelligence / Profile preview

Qizhi capsule

Development stage: Phase 2
Lead developer: Shanghai Zhongyao Biotechnology
Administration: Oral

Overview

**Qizhi capsule** is a Chinese traditional medicine product developed by Shanghai Zhongyao Biotechnology for evaluation in metastatic castration-resistant prostate cancer. It has been studied as an oral adjunct to abiraterone acetate plus prednisone acetate in patients with prostate-specific antigen progression after prior abiraterone/prednisone therapy. The registered study is a randomized, double-blind, placebo-controlled, multicenter Phase IIa dose-exploration trial in patients characterized in traditional Chinese medicine as having stasis-heat internal accumulation syndrome. Its individual active constituents and molecular mechanism have not been reliably identified in public sources for the exact product named 七芝胶囊. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/6c2395e4806e49d1a5503ac8b168f922))

Other names: 七芝胶囊

Beyond the preview

Go deeper on Qizhi capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qizhi capsule.